Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance

NCT05160974 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05160974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05160974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
QTERN (SAXAGLIPTIN/DAPAGLIFLOZIN FDC) Regulatory Post-Marketing Surveillance
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
December 30, 2021
Completion date
April 1, 2024
Enrollment
679 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus